BOSTON, March  27, 2026  (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

Cue Biopharma Announces CEO Transition

Lucinda Warren Appointed Interim CEO of Cue Biopharma Amid Key Developments

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>BOSTON, March  27, 2026  (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Lucinda Warren has been named interim CEO of Cue Biopharma following Usman Azam&#039;s resignation. Warren&#039;s focus will be on advancing CUE-401 into clinical trials by the second half of 2026, which could catalyze investor interest given the drug&#039;s potential in treating autoimmune diseases.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Lucinda Warren appointed interim CEO of Cue Biopharma.</li><li>Former CEO Usman Azam has stepped down effective March 26, 2026.</li><li>Warren aims to advance CUE-401 into the clinic by H2 2026.</li><li>Cue Biopharma focuses on selective T cell modulation for autoimmune diseases.</li><li>Recent collaborations enhance CUE-401&#039;s development trajectory.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Boehringer Ingelheim (BI)</strong>: Strategic collaboration enhances CUE-401&#039;s development potential.</li><li><strong>ImmunoScape (N/A)</strong>: Collaboration may improve Cue&#039;s pipeline and market competitiveness.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The news falls under Corporate Developments as it involves management changes and strategic focus shifts. Leadership stability is vital in biotech, impacting operational execution and investor confidence.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>CUE-401&#039;s scheduled progression into clinical trials by H2 2026 may attract new investments.</li><li>Leadership transition may improve operational strategies leading to enhanced project focus.</li><li>Successful execution of collaborations with companies like Boehringer Ingelheim may boost CUE&#039;s market position.</li><li>Investor sentiment could shift positively with progress reports or trial milestones for CUE-401.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Lucinda Warren was previously Cue&#039;s chief financial and business officer.</li><li>Usman Azam resigned as CEO on March 26, 2026.</li><li>CUE-401 targets autoimmune and inflammatory diseases using innovative biologics.</li><li>Warren plans to advance CUE-401 into the clinic by H2 2026.</li><li>Cue has valuable collaborations with ImmunoScape and Boehringer Ingelheim.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>CUE may experience upward movement as leadership changes focus on clinical progression.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>BOSTON, March  27, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Ej2eDfR0ocFCblLMRvoG3WYwpGqt3eUGMGa0p1USOJHycvdmlCHAst8zGBVdSxMr9CdlSLqa9GBc3ESqiJGIBFJdgoGIWoB0l_pdVlLA_7PsN-83cBKsltc5NCSZAg3AXcD7RZ4NtSu-m3jG3HzZPhabsaLr8Jeovl8CYywr2YGtsxywrTtcVAEFFc2_30FCEnsvwjjI_liiwYsE1LTpJBnoVmcJIUnSeENGuEGHn5VqiWx0vI37l2cOYnZMfudcU5O18FbAw2e9ZsSOEggbCw==" rel="nofollow" target="_blank">Cue Biopharma, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CUE">CUE</a>), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that Lucinda Warren, an industry veteran who has served as Cue Biopharma's chief financial and business officer since February 2026 and previously as Cue Biopharma's chief business officer from September 2024 until February 2026, has been appointed interim president and chief executive officer (CEO). Usman Azam has stepped down as president and CEO and as a director, effective March 26, 2026.</p>  <p>"The board of directors thanks Usman for his services to Cue," said Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma. "Furthermore, we are delighted that Lucinda has accepted to step into the president and CEO role during this transition period. Lucinda has successfully executed multiple valuable deals for the Company in the past year, including the return of worldwide development and commercialization rights for CUE-401, our collaboration with Boehringer Ingelheim for CUE-501, and our strategic collaboration and license agreement with ImmunoScape to develop a breakthrough cell therapy for solid tumors. The board is fully supportive and behind Lucinda in her new role, as Cue progresses CUE-401 toward the clinic, and as we continue to pursue creative deals to build value for our shareholders."</p>  <p>Ms. Warren, added, "I'm honored and committed to lead Cue Biopharma at this time, focused on continuing to drive our key priority of moving CUE-401 into the clinic by the second half of this year."</p>  <p>Ms. Warren has over 30 years of global experience in the pharmaceutical and biotechnology sectors. Prior to joining Cue Biopharma, she served as vice president of business development for Neuroscience and Japan Regionally at Johnson &amp; Johnson, a healthcare products company, where she was responsible for end-to-end business development, including licensing, mergers and acquisitions, and alliance management. Her leadership was instrumental in optimizing resources, fostering high-performing teams, and cultivating strong relationships with stakeholders. Ms. Warren's extensive experience also includes significant roles at Janssen Cilag Australia and Janssen Biologics, where she led business units and managed global transitions, consistently delivering value through strategic transactions. She currently serves as chairman of the board of International School Services, contributing her expertise in finance and governance. Ms. Warren holds a B.S. in biological sciences with a minor in neurology from the University of Alberta. <br></br><br></br><strong>About Cue Biopharma</strong><br></br>Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT&#xAE; <em>(Selective Targeting and Alteration of T cells)</em> and biologics are designed to harness the curative potential of the body's intrinsic immune system without the adverse effects of broad systemic immune modulation. CUE-401, the company's lead autoimmune asset, is designed to act mechanistically both as a regulator of proinflammatory mechanisms, and as a master switch for regulatory T cell (Treg) differentiation to induce tolerance. It is a highly innovative, tolerogenic bifunctional molecule combining a TGF-beta breathing-mask moiety with Cue Biopharma's clinically validated interleukin 2 (IL-2) mutein in a single injectable biologic.</p>  <p>Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.</p>  <p>For more information please visit <a href="https://www.globenewswire.com/Tracker?data=4G1zVe9XXQ6vUQeWUoi5WFOSU6bBOW7cYdoBYrobrIr6N-5uwDJVBG6ruO_u7gqJj4UAUkb0RKYoudDjwd8L3qNvyOFBlIzaCsrL5zQ1qMYy5wMkgmyLrKjSYw-WNOpYV9qGcytHR4wbd8dXNKIRx6h6Ul8uQAyeURD4bHH8odR8cUMZZGKcUvBWa-d1hfifXtQH33drA1O8O4KjpvxhsRtBO1vp7XgRHznZG7Mb2pk6kuU3uKPl_uNURfGX_kuL1cO-HZeG4Rm48J4LNekQW9yivBmW0EKHiF455HTznx50QOBDyOMVShW7rUn0o-AYx3GnRutn5ThmBc_zAvkAgBCil5wdnfbFG_y8LT8xn5ynh0i6DGCmSYMHy_1R0DuGQJJD3PaDRYxvQrQO4GUBnGFYGY9hXbQ7jTwkMtLRFhlf5XDHJm5hzfsmbjkt2oPZuEHNBE6BTigYn7VcpTUxzG0weaWRWD6ttqG5u8S-S95AEIoKTl-5owFQeR_MowLP" rel="nofollow" target="_blank">www.cuebiopharma.com</a> and follow us on <a href="https://www.globenewswire.com/Tracker?data=tzVr-Ll9szZ3aFnxoba3vGVGMDSOAfzwNrvDE5fXTt9lwIfraNJHFCN9as8PnzmaTdkaQ60EfLcaywcWUqN7LA3uttJ_cOgpeHjmT7hXt3hlV9DAr526cQtb03kmFQgQvWhZ3m3IOYBl_Ku-rXKAI5mf2iyHTVtRIQMb5c6PvoElbrhwu2dr84WFx6Ptjby0-nmkBUGZFlpsK50vymfz_kxM8SMU3mKE0trHJR3nGO8I8Q0zSp7clK92FEOzTU7wdWchkr5cQsBfVr_zLUI4FxGQmplbs1e-toXqLLDrF50tBweemMl8-bZ-IobXdh1ABDVbi_VTQ6EXPAOhiTWpAG_TifiaJGafp7gXenbIK6kr15gd1avuLMz1ZVtgUkTdagIfpKgRwfDmuetzprwuXMlVBU9FOdrYCsx7ZVFaM7ZK-wJvWGGQgffGAD0MS--dyvZrpgustJFpvwV3u4Ji6Q==" rel="nofollow" target="_blank">X</a> and <a href="https://www.globenewswire.com/Tracker?data=BhdjEe5ERP0CC56e9LFvvgN1azGBOvaH_cH7b8vowtadVvRMOKm0lbaKvGPr2Awvbt8Y_66-zAbNoK5v7ARoBammPOZvO8SVcdvRW2fSCXDzbleznVJaE45D-t1n-oEeJHYAMPeiADfhveEu2h4xnScJxUrtDA-t-IV0Q9nDYtycp_aOHaiqEpT4qbD1bijbZLQb-4V0MBSbd6M_Hhp11tlImh8ZqwJx7_dporgRK5WDGbFKx88wL_czzhmkC1Qv" rel="nofollow" target="_blank">LinkedIn</a>.<br></br><br></br><strong>Forward-Looking Statements </strong><br></br>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company's belief regarding the potential benefits and applications of its drug candidates and programs, including the company's plans to further advance its differentiating Immuno-STAT&#xAE; platform and lead autoimmune asset, CUE-401, including the company's plans to move CUE-401 into the clinic by the second half of 2026; and the company's business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "promise" or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company's ability to maintain its collaboration with ImmunoScape; the company's limited operating history, limited cash and a history of losses; the company's ability to obtain adequate financing to fund its business operations in the near term and successfully remediate its current "going concern" determination that it does not have sufficient capital on hand to continue operations beyond the next twelve months; the company's ability to achieve profitability; potential setbacks in the company's research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration (FDA) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company's operations and clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company's reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company's ability to obtain adequate financing to fund its business operations in the future and ability to continue as a going concern; the company's ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management&#39;s Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p>  <p><strong>Investor Contact</strong><br></br>Marie Campinell<br></br>Senior Director, Corporate Communications<br></br>Cue Biopharma, Inc.<br></br><a href="https://www.globenewswire.com/Tracker?data=DlLDnid-UpA5YmH1vlbTLWwxUNUrsxaiNWDVbF_6LYjiqazCvXBRu1szM91KorZ-7JmetCncKeE9gK2-y3fu3bUk7oFWoINKJRBZnu5lgDAf3J0kgvrmRq2RsUaXrtuzKtuihIoRe8suLYxPM9lxQhCfeq-Y-YVuX55Pgo5ZyihLbucSMDZS5guNbMHbVinynX8XJyMeoGwSwGr9CULuHADVPaFKtguHljeTzl0FUjia-LQghFvZ52wHXfJZI7hGANEdnu0jrzMODfBp2muDsQ==" rel="nofollow" target="_blank">mcampinell@cuebio.com</a></p>  <p><strong>Media Contact</strong><br></br>Jonathan Pappas<br></br>LifeSci Communications<br></br><a href="https://www.globenewswire.com/Tracker?data=sucZG2RsLRd9SRnKst790Ha86ink1bgLc_iKa8D9PrMgdzxEmRDV4DZ59zhN8FwxbGWM9iREjvoh_lpzi5HF052Dl8rtSvspoYPSVq749Kg8AmAHqlBNX73BfhFTcWtX" rel="nofollow" target="_blank">jpappas@lifescicomms.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3OTk0MCM3NTA3Njg5IzIwOTI2OTI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/MTNmY2U3OTctYWE1My00MTQ3LWI1ZDUtM2EyYTY4MTBlYTc4LTExMDQyNjMtMjAyNi0wMy0yNy1lbg==/tiny/Cue-Biopharma-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/10541379-34cc-4869-a26f-fd99feead42a"><img src="https://ml.globenewswire.com/media/10541379-34cc-4869-a26f-fd99feead42a/small/cue-bio-brand-strategy-graphics-jpg.jpg" border="0" width="150" height="55" alt="Primary Logo"></img></a></p>

Lucinda Warren has been named interim CEO of Cue Biopharma following Usman Azam's resignation. Warren's focus will be on advancing CUE-401 into clinical trials by the second half of 2026, which could catalyze investor interest given the drug's potential in treating autoimmune diseases.

Cue Biopharma Announces CEO Transition

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News